Candel Therapeutics, Inc. (CADL)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 15K 30K 45K Q1 '20: 32K Q2 '20: 31K Q3 '20: 31K Q4 '20: 31K Q1 '21: 31K Q2 '21: 31K Q3 '21: 31K Q4 '21: 31K Q1 '22: 31K Q2 '22: 31K Q3 '22: 31K Q4 '22: 31K Q2 '20 Q4 '20 Q2 '21 Q4 '21 Q2 '22 Q4 '22

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-30M -20M -10M 0 10M 20M 30M Q1 '20: -2.3M Q2 '20: -2.6M Q3 '20: -2.7M Q4 '20: -6.1M Q1 '21: -4.7M Q2 '21: -5.3M Q3 '21: -8M Q4 '21: -7.7M Q1 '22: -9M Q2 '22: -8.8M Q3 '22: -8.9M Q4 '22: -8.1M Q1 '23: -9.6M Q2 '23: -9.6M Q3 '23: -8.9M Q4 '23: -10.3M Q1 '24: -7.9M Q2 '24: -8.6M Q3 '24: -8.8M Q4 '24: -8.1M Q1 '25: -8.1M Q2 '25: -11.2M Q3 '25: -13.2M Q4 '25: -15.8M Q1 '26: -16.3M Q2 '26: -26.7M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Net Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q1 '20: -1.8M Q2 '20: -2.9M Q3 '20: -2.6M Q4 '20: -10.5M Q1 '21: -4.5M Q2 '21: -17.1M Q3 '21: -16.2M Q4 '21: 1.6M Q1 '22: -874K Q2 '22: -4.1M Q3 '22: -8.7M Q4 '22: -5.1M Q1 '23: -8.8M Q2 '23: -9.6M Q3 '23: -8.4M Q4 '23: -11.1M Q1 '24: -8.2M Q2 '24: -22.2M Q3 '24: -10.6M Q4 '24: -14.1M Q1 '25: 7.4M Q2 '25: -4.8M Q3 '25: -11.3M Q4 '25: -29.5M Q1 '26: -8.9M Q2 '26: -38.9M Q2 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '20: -1.5M Q4 '20: -3.4M Q1 '21: -5.6M Q2 '21: -4.5M Q3 '21: -6.9M Q4 '21: -5.2M Q1 '22: -8.1M Q2 '22: -7.1M Q3 '22: -9.4M Q4 '22: -6.9M Q1 '23: -10.8M Q2 '23: -7.2M Q3 '23: -8.8M Q4 '23: -7.4M Q1 '24: -8.4M Q2 '24: -6.2M Q3 '24: -6.6M Q4 '24: -5.8M Q1 '25: -8.6M Q2 '25: -8.9M Q3 '25: -10.2M Q4 '25: -10.6M Q1 '26: -18M Q2 '26: -17.2M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-21M -14M -7M 0 7M 14M 21M Q3 '20: -2.2M Q4 '20: -3.9M Q1 '21: -5.9M Q2 '21: -5.2M Q3 '21: -7.3M Q4 '21: -5.7M Q1 '22: -8.2M Q2 '22: -7.7M Q3 '22: -9.6M Q4 '22: -7.2M Q1 '23: -11M Q2 '23: -7.4M Q3 '23: -8.9M Q4 '23: -7.5M Q1 '24: -8.4M Q2 '24: -6.2M Q3 '24: -6.6M Q4 '24: -5.8M Q1 '25: -8.6M Q2 '25: -8.9M Q3 '25: -10.4M Q4 '25: -11M Q1 '26: -18.7M Q2 '26: -17.3M Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 30M 60M 90M Q2 '21: 11.7M Q3 '21: 23.3M Q1 '22: 28.7M Q2 '22: 28.8M Q3 '22: 28.9M Q1 '23: 28.9M Q2 '23: 28.9M Q3 '23: 28.9M Q1 '24: 29.2M Q2 '24: 29.9M Q3 '24: 32M Q1 '25: 54.8M Q2 '25: 51.5M Q3 '25: 54.9M Q1 '26: 62.4M Q2 '26: 74.1M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-4.50 -3.00 -1.50 0.00 1.50 3.00 4.50 Q4 '20: -1.52 Q1 '21: -1.75 Q2 '21: -2.96 Q3 '21: -3.43 Q4 '21: -1.91 Q1 '22: -1.56 Q2 '22: -0.24 Q3 '22: 0.15 Q4 '22: -0.64 Q1 '23: -0.91 Q2 '23: -1.10 Q3 '23: -1.09 Q4 '23: -1.30 Q1 '24: -1.28 Q2 '24: -1.69 Q3 '24: -1.73 Q4 '24: -1.74 Q1 '25: -1.33 Q2 '25: -0.68 Q3 '25: -0.56 Q4 '25: -0.72 Q1 '26: -0.99 Q2 '26: -1.42 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.